Stock Evaluator: Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY)
Shanghai Pharmaceuticals Holding Co., Ltd SHPMY
$7.47
0.00
0.00%
August 10, 2026 11:35:16 AM
EST
Volume: 0
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
| DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Providers & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others. It offers chemical and biological drugs, Chinese medicine, health care products, and medical devices to treat immunology, psychiatric and neurological, tumor, cardiovascular, digestive metabolism, psychoneurotic, neoplasm, respiratory system, and anti-infection diseases, as well as invests in equity. The company also engages in the provision of pharmaceutical distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it engages in the operation of a network of retail pharmacy stores. Shanghai Pharmaceuticals Holding Co., Ltd. was incorporated in 1994 and is headquartered in Shanghai, China.
Financial Summary
| Share Statistics | SHPMY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8,276.6 | $1,982.5 | 75% |
|
| Shares Out (Mil) | 537.7 | 77.7 | 89% |
|
| Institutional Ownership | 50.0% | 86.1% | 30% |
|
| Float (Mil) | 1,507.9 | 52.1 | 94% |
|
| Beta | 0.21 | 0.75 | 13% |
|
| Avg Daily Volume (000s) | 1 | 637 | 4% |
|
| Price Change (52-week) |
2.9% | 79.7% | 47% |
|
| Growth | SHPMY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 6.6% | 10.9% | 44% |
|
| Net Income (5yr) | 3.5% | (1.6%) | 45% |
|
| EPS (5yr) | (1.9%) | 0.3% | 29 |
|
| Dividends (5yr) | (1.8%) | 0.0% | 55% |
|
| Cash Flow (5yr) | (21.9%) | (17.9%) | 30% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SHPMY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $41,766 | $1,504 | 96% |
|
| Net Income (TTM) (Mil) | $842 | $28 | 84% |
|
| EPS (TTM) | $0.227 | $0.200 | 47% |
|
| Operating Cash Flow (TTM) (Mil) | $1,065 | $162 | 81% |
|
| Net Cash Flow (TTM) (Mil) | ($767) | $9 | 4% |
|
| Long-Term Debt (Q1) (Mil) | $684 | $338 | 62% |
|
| Enterprise Value (Q1) (Mil) | $12,529 | $2,416 | 77% |
|
| Valuation | SHPMY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.79 | na |
|
| P/E | na | 25.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | SHPMY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 10.8% | 27.8% | 10% |
|
| Net Margin | 2.0% | 1.2% | 38% |
|
| ROA | 2.6% | 2.2% | 59% |
|
| ROE | 7.9% | 7.2% | 51% |
|
| Liabilities to Assets | 61.1% | 58.6% | 55% |
|
| F-Score | na | 5 | na |
|
Shanghai Pharmaceuticals Holding Co., Ltd did not pass any screens on 8/20/2026.
